Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
May 7, 2025
The Biotechnology Innovation Organization (BIO) offers this submission in response to the request by the Department of Commerce for comments on section 232 national security investigation of imports of pharmaceuticals and pharmaceutical ingredients. This investigation presents a critical opportunity to examine the intricacies of biotechnology supply chains and chart a path forward that strengthens national resilience while keeping the United States at the forefront of scientific innovation.
Dear Colleagues, I am just past the two-year mark as BIO’s President & CEO, which arrives as we find ourselves at a defining moment for the future of biotechnology. For fifty years, our industry has delivered one of the great…
The Biotechnology Innovation Organization (BIO) offers this submission in response to the request by the Department of Commerce for comments on section 232 national security investigation of imports of pharmaceuticals and pharmaceutical ingredients. This investigation presents a critical opportunity to examine the intricacies of biotechnology supply chains and chart a path forward that strengthens national resilience while keeping the United States at the forefront of scientific innovation.